Pareschi R, Mincione A, Destito D, Mola M, Righini S, Assi A, Dottorini M
Otorhinolaryngology Unit, Civil Hospital of Legnano, MI, Italy.
Acta Otorhinolaryngol Ital. 2004 Dec;24(6):348-53.
Diagnosis and treatment of thyroid carcinoma require a multidisciplinary approach. The close and long-standing collaboration between the Otorhinolaryngology, Pathological Anatomy and Nuclear Medicine Departments of Legnano Hospital has led to a precise diagnostic and therapeutic protocol in thyroid patients. In the 1990-2002 period, 131 patients underwent total thyroidectomy after diagnosis of thyroid cancer at the Otorhinolaryngology--Head and Neck Surgery Department. Patients submitted to lobectomy for differentiated thyroid cancer were excluded from the present study. The patient population is composed of 96 females (73%) and 36 males (27%) aged between 22 and 85 years. Of the 131 patients, 115 (87%) presented papillary carcinoma, 13 (10%) follicular carcinoma, 2 (2%) medullary carcinoma and one (1%) undifferentiated carcinoma. Two patients (2%) suffered from a preoperative monolateral recurrent nerve palsy. Total thyroidectomy was performed in all 131 patients. Selective neck dissection was performed only in patients with positive lymph nodes for papillary (37/115, 32%) and follicular carcinoma histotype (2/13, 15%) and, in both patients with medullary carcinoma (100%). Of the 131 patients, 15 (11%) did not undergo routine follow-up and were, therefore, excluded from the study, the remainder completed a mean follow-up of 47 months. During follow-up, the incidence of the two most frequent complications of thyroid surgery were evaluated: recurrent nerve paralysis and permanent hypoparathyroidism (exceeding the postoperative 6 months). Results of treatment have been evaluated considering the incidence of local and/or distant recurrences and patient survival rate. As far as concerns papillary and follicular histotype, we have considered as healed (absence of signs suggesting loco regional and distant recurrence) only those patients presenting both negligible levels of plasma thyroglobulin and a negative total-body 131I scintigraphy. Briefly, in 3 cases (3%), all papillary carcinomas, local recurrence occurred; 9 (8%), all with papillary carcinoma, developed lateral neck recurrence; 6 (5%), 5 with papillary carcinoma and one with follicular carcinoma, developed distant metastases, of which 3 pulmonary, 2 bone and 1 hepatic. Serum thyroglobulin values were considered during the last control visit in 95/113 patients (84%). Of these, 86 (91%) with negligible thyroglobulin levels and negative 131I scintigraphy, were considered healed. All 113 patients with differentiated thyroid carcinoma were alive at the last control visit. Both patients with medullary carcinoma are alive with no sign of illness at the last follow-up control. The patient presenting undifferentiated carcinoma died 2 months after surgery. In conclusion, at the last follow-up control, 1 (1%) patient has died, 5 patients (4%) are alive with disease (2 of whom suffered from multiple recurrences) and the remaining 110 (95%) patients are alive without evidence of disease. As far as concerns complications of surgery, iatrogenic recurrent palsy and permanent hypoparathyroidism are present in 2 (2%) and 10 patients (8%), respectively.
甲状腺癌的诊断和治疗需要多学科方法。莱尼亚诺医院耳鼻喉科、病理解剖科和核医学科之间密切且长期的合作,已形成了针对甲状腺患者精确的诊断和治疗方案。在1990年至2002年期间,131例患者在耳鼻喉头颈外科被诊断为甲状腺癌后接受了全甲状腺切除术。因分化型甲状腺癌接受叶切除术的患者被排除在本研究之外。患者群体由96名女性(73%)和36名男性(27%)组成,年龄在22岁至85岁之间。131例患者中,115例(87%)为乳头状癌,13例(10%)为滤泡状癌,2例(2%)为髓样癌,1例(1%)为未分化癌。2例患者(2%)术前出现单侧喉返神经麻痹。131例患者均接受了全甲状腺切除术。仅对乳头状癌(37/115,32%)和滤泡状癌组织学类型(2/13,15%)有阳性淋巴结的患者以及2例髓样癌患者(100%)进行了选择性颈淋巴结清扫术。131例患者中,15例(11%)未接受常规随访,因此被排除在研究之外,其余患者平均随访47个月。在随访期间,评估了甲状腺手术最常见的两种并发症的发生率:喉返神经麻痹和永久性甲状旁腺功能减退(超过术后6个月)。已根据局部和/或远处复发的发生率以及患者生存率评估了治疗结果。就乳头状和滤泡状组织学类型而言,我们仅将那些血浆甲状腺球蛋白水平可忽略不计且全身131I闪烁扫描为阴性的患者视为治愈(无提示局部区域和远处复发的体征)。简而言之,3例(3%)均为乳头状癌患者出现局部复发;9例(8%)均为乳头状癌患者出现颈部侧方复发;6例(5%),5例为乳头状癌,1例为滤泡状癌,出现远处转移,其中3例为肺转移,2例为骨转移,1例为肝转移。95/113例患者(84%)在最后一次对照访视时检测了血清甲状腺球蛋白值。其中,86例(91%)甲状腺球蛋白水平可忽略不计且131I闪烁扫描为阴性的患者被视为治愈。113例分化型甲状腺癌患者在最后一次对照访视时均存活。2例髓样癌患者在最后一次随访对照时均存活且无疾病迹象。未分化癌患者术后2个月死亡。总之,在最后一次随访对照时,1例(1%)患者死亡,5例(4%)患者带病存活(其中2例患有多处复发),其余110例(95%)患者存活且无疾病证据。就手术并发症而言,医源性喉返神经麻痹和永久性甲状旁腺功能减退分别出现在2例(2%)和10例患者(8%)中。